Hilde Windels

Ms. Hilde Windels is an Independent Director at PHAXIAM Therapeutics SA, a Chief Executive Officer & Director at Antelope Dx BV, a Chairman at Celyad Oncology SA, an Independent Non-Executive Director at MDxHealth SA, an Executive Chairman & Co-Chief Executive Officer at MyCartis NV and an Independent Director at Gimv NV.
She is on the Board of Directors at PHAXIAM Therapeutics SA, Antelope Dx BV, MDxHealth SA, Windels Hilde BV, Microphyt SA and Gimv NV.
Ms. Windels was previously employed as an Independent Director by Ablynx NV, an Independent Director by ERYTech Pharma SA, an Executive Director by Biocartis Group NV, a Chief Executive Officer by Biocartis SA, a Chief Financial Officer & Director by deVGen NV, a Manager by ING Bank NV, Amsterdam, succursale de Lancy/Genève, a Chief Financial Officer by SEPS Pharma NV, and a Chief Financial Officer by TiGenix NV.
She also served on the board at Vlaams Instituut voor Biotechnologie - Flanders Institute and FlandersBio vzw.
She received her graduate degree from Katholieke Universiteit Leuven.